Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic hematopoietic stem cell transplantation in Philadelphia acute lymphoblastic leukemia Experiencia del Grupo Español de Trasplante Hematopoyético (GETMON-GETH) en el trasplante alogénico de progenitores hematopoyéticos en leucemia aguda linfoblástica Philadelphia
Galán Gómez, Víctor (Hospital Universitario La Paz (Madrid))
de la Fuente Regaño, Lydia (Universidad Autónoma de Madrid. Facultad de Medicina)
Rodríguez Villa, Antonia (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron)
González Vicent, Marta (Hospital Infantil Universitario Niño Jesús (Madrid))
Badell Serra, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Fernández, José María (Hospital Universitari i Politècnic La Fe (València))
Pascual Martínez, Antonia Isabel (Hospital Materno Infantil Carlos Haya. Hemato-Oncología Pediátrica)
Pérez Hurtado, José María (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
López Duarte, Mónica (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Maldonado Regalado, M.Soledad (Hospital Universitario Ramón y Cajal (Madrid))
Pérez-Martínez, Antonio (Hospital Universitario La Paz (Madrid))

Data:	2022
Resum:	Introduction: Outcomes in patients diagnosed of acute lymphoblastic leukemia with Philadelphia chromosome (Ph-ALL) remains unfavourable compared to other subtypes of acute lymphoblastic leukemia despite improvements in drug treatments as well as advances in hematopoietic stem cell transplantation (HSCT). Patients and methods: The role of allogeneic HSCT in Ph-ALL patients has been analysed through a multicentric study where data belonging to 70 patients diagnosed of this entity in different center that received HSCT between years 1998 and 2014, were reported by the Grupo Español de Trasplante Hematopoyético (GETH). Results: The performance of HSCT from year 2004, in first complete remission (CR) status with thymoglobulin (ATG) based conditioning had a favorable impact on overall survival (OS). HSTC performance from year 2004, in first CR with ATG-based conditioning in addition to acute graft versus host disease (aGvHD) development, increased event free survival (EFS). Treatment with imatinib as well as undetectable minimal residual disease (MRD) prior to HSCT, combined with aGvHD, reduced risk of relapse (RR). Patient age less than 10 years when HSCT, first CR and ATG-based conditioning were associated to a lower transplant related mortality (TRM). Conclusions: Patients that could achieve first CR that also received ATG-based conditioning had a better OS and EFS, so HSCT should be considered for this group of patients.
Ajuts:	Instituto de Salud Carlos III PI18/01301
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Castellà
Document:	Article ; recerca ; Versió publicada
Matèria:	Acute lymphoblastic leukemia ; Philadelphia chromosome ; BCR/ABL ; Hematopoietic stem cell transplantation ; Imatinib ; Graft versus host disease
Publicat a:	Anales de pediatría, Vol. 96 Núm. 4 (abril 2022) , p. 309-318, ISSN 1695-9531

DOI: 10.1016/j.anpedi.2021.02.015

10 p, 723.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats